Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33157042.
- Also identified by DOI 10.1016/j.stem.2020.10.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most patients with AML succumb to chemoresistant leukemia stem cells (LSCs), which persist and reinitiate disease years after clinical remission. In this issue of Cell Stem Cell, Jones et al. (2020) identify a therapeutically targetable mechanism of resistance to venetoclax in relapsed and refractory AML LSCs mediated by nicotinamide metabolism.
Medical subject headings
- Leukemia, Myeloid, Acute
- Neoplastic Stem Cells